Navigation Links
Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients
Date:2/14/2008

Administering More Than 180,000 Patient Visits Each Year, East Coast's

Largest Independent Clinical Lab Services Company Aspires to Empower

Patients with Control Over Medical Care

CEDAR KNOLLS, N.J., Feb. 14 /PRNewswire-FirstCall/ -- MedeFile International, Inc. (OTC Bulletin Board: MDFI), a company specializing in portable electronic medical records management solutions, today announced that it has signed a collaborative marketing agreement with Hayes Clinical Laboratory, the largest independent clinical laboratory on Florida's East Coast.

With five locations in Southern Florida and a service region that covers primarily Palm Beach, Broward, Okeechobee, St. Lucie and Martin counties, Hayes Labs is a full service medical laboratory performing tests on all body fluids and tissue. Each year, Hayes administers more than 180,000 patient visits, most of which have been referred from its client base comprised of nearly 500 doctors and healthcare specialists.

Chad Fredrich, President of Hayes, noted, "We routinely see patients who are subjected to redundant clinical testing because they are under the care of physicians who are unaware of other medical providers that are also treating the patient for related or unrelated medical conditions and who have ordered similar tests. This unnecessary redundancy is costly to the patient and costly to the healthcare system. Moreover, insurance payers may refuse to approve payment for testing when patients have exceeded 'frequency limitations' allowable for clinical tests, resulting in our having to write off these billings as bad debt. In this case, testing redundancy is costly to our company. By empowering patients with MedeFile, they gain control over effectively managing their own medical records, can carry actual clinical test results with them wherever they go, and can optimize the care they receive from their treating physicians. We are very excited about teaming with MedeFile International to begin offering this novel, cost-saving solution to the thousands of patients who rely on Hayes for clinical testing services."

Hayes Labs will also engage in actively encouraging its network of referring physicians, in addition to other independent clinical laboratories around the country, to offer MedeFile to their respective patient bases.

"MedeFile is on a mission to educate the nation's healthcare community on the fact that centralizing actual medical records with the patient is the key to achieving real, positive change to the U.S. healthcare delivery system. By winning the support of respected medical institutions and providers, such as Hayes Labs, we are succeeding in helping others to realize and appreciate the many important convenience, care-enhancing and cost-saving benefits made possible with the MedeFile solution," stated Milton Hauser, Chairman and CEO of MedeFile.

About MedeFile International, Inc.

MedeFile has developed a proprietary system for gathering and digitizing medical records so that individuals can have access to a comprehensive set of their medical records. MedeFile's primary product is the MedeFile system, a highly secure system for gathering and maintaining medical records. The MedeFile system is designed to gather all of its members' actual medical records and create a single resource that is accessible 24 hours a day, seven days a week.

Representing an advanced, yet easy-to-use, approach to portable, electronic medical records management, MedeFile combines state-of-the-art technology and the Internet to make medical data instantly accessible to each MedeFile subscriber and his or her authorized healthcare providers from anywhere in the world. In addition to accessing one's medical records through MedeFile's secure Internet portal found at http://www.MedeFile.com, members can carry their entire medical history and emergency information wherever they go on a unique device called a MedeDrive -- a proprietary USB drive designed to be carried on a keychain. The MedeDrive plugs into any USB port of a Windows-based PC; and because MedeDrive automatically loads its own viewer, users do not require any special programs or software to view data. MedeMobile provides on-the-go subscribers with the ability to enjoy even greater flexibility and access to their personal health information wherever and whenever they need it.

For more information about MedeFile and the MedeFile system, visit http://www.medefile.com.

Safe Harbor Statement Under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of MedeFile could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to respond to the evolving technological landscape, inability to finance the Company's operations or expansion, inability to hire and retain qualified personnel, competitive pressure, changes in the general economic climate, including rising interest rates, and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, and such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, review our SEC filings.

FOR MORE MEDEFILE INFORMATION, PLEASE CONTACT:

Investors/Stockbrokers/Institutions/Media

Elite Financial Communications Group, LLC/Elite Media Group

Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist

407-585-1080 or via email at mdfi@efcg.net


'/>"/>
SOURCE MedeFile International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
3. New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans
4. Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG
5. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
8. Contract Services for Big Pharma and Biotechs Driving Growth and Innovation from Discovery to Clinical Trials
9. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
10. Medpace Hires Clinical Pharmacologist, Jim Wei, MD, PhD
11. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in an ... on RFD-TV. , With global population estimates nearing ten billion people by 2050, ... a growing nation. At the same time, many of our valuable resources are becoming ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):